Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saroj Niraula

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Cancer Treatment Reviews|February 29, 2016
Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trialsJeffrey Graham, Marshall Pitz, Vallerie Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysisSaroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2013
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 studySaroj Niraula, Greg Pond, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugsSaroj Niraula, Bostjan Seruga, Alberto Ocana, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 31, 2020
Off-label infusion of biosimilar bevacizumab: A provincial experienceMarc Geirnaert, Jacy Howarth, Curtis Kellett, et al.
Future Science OA|December 20, 2017
Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancerSaroj Niraula, Arnoud J Templeton, Francisco Vera-Badillo, et al.
The Lancet. Oncology|December 8, 2016
Relevance of randomised controlled trials in oncologyIan F Tannock, Eitan Amir, Christopher M Booth, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 10, 2019
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort StudyWilliam D Leslie, Suzanne N Morin, Lisa M Lix, et al.
The Oncologist|July 12, 2019
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort StudyWilliam D Leslie, Suzanne N Morin, Lisa M Lix, et al.
The Prostate|January 16, 2016
Study of testosterone-guided androgen deprivation therapy in management of prostate cancerSaroj Niraula, Arnoud J Templeton, Francisco E Vera-Badillo, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Cancer Treatment Reviews|February 29, 2016
Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trialsJeffrey Graham, Marshall Pitz, Vallerie Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysisSaroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2013
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 studySaroj Niraula, Greg Pond, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugsSaroj Niraula, Bostjan Seruga, Alberto Ocana, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 31, 2020
Off-label infusion of biosimilar bevacizumab: A provincial experienceMarc Geirnaert, Jacy Howarth, Curtis Kellett, et al.
Future Science OA|December 20, 2017
Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancerSaroj Niraula, Arnoud J Templeton, Francisco Vera-Badillo, et al.
The Lancet. Oncology|December 8, 2016
Relevance of randomised controlled trials in oncologyIan F Tannock, Eitan Amir, Christopher M Booth, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 10, 2019
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort StudyWilliam D Leslie, Suzanne N Morin, Lisa M Lix, et al.
The Oncologist|July 12, 2019
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort StudyWilliam D Leslie, Suzanne N Morin, Lisa M Lix, et al.
The Prostate|January 16, 2016
Study of testosterone-guided androgen deprivation therapy in management of prostate cancerSaroj Niraula, Arnoud J Templeton, Francisco E Vera-Badillo, et al.
Pageof 4